Tag:

Neupogen

Latest Headlines

Latest Headlines

Amgen to whack 160 jobs

Amgen's earnings last week were not half bad. But they were not good enough to save the jobs of 160 employees whom the company says it will let go.

Teva's Neupogen-knockoff approval highlights slow progress of biosims

The FDA has handed an approval to Teva for its biosimilar of the aging neutropenia drug Neupogen. But the significant barriers that lie between that treatment--tbo-filgrastim--and any kind of significant market share underscores just how slowly these new therapies will begin to reshape the U.S. drug market.

Teva's Neupogen knockoff faces uphill battle for share

Teva Pharmaceutical Industries ($TEVA) has pegged its future on becoming a hybrid drugmaker, with generics and brands working in perfect synergy. That's because it has looked past the huge wave of patent expirations on blockbuster drugs, and concluded that generics growth alone won't be respectable enough. And that's why it bought Cephalon last year.

Amgen founding CEO George Rathmann dies at 84

In the years after he took the helm of the company, Rathmann helped steer the development of Epogen and Neupogen. Only now does Amgen face rivals to its anemia franchise.

Fake Avastin may not be the only counterfeit on doctors' shelves

As doctors search their shelves for the counterfeit Avastin flagged by Roche ($RHHBY) and the FDA yesterday, officials are also hunting down illegally imported, unauthorized versions of other pricey

Hospira gains EMA OK for Neupogen biosimilar

Hospira says that it won European approval for its follow-on therapy to Amgen's blockbuster Neupogen. In winning the OK, Hospira provided late-stage data demonstrating that its therapy, Nivestim...

Amgen joins the Teva-fighting club

Teva Pharmaceutical Industries has officially become a thorn in Amgen's side. The Israeli generics giant has asked FDA to approve its biotech drug designed to increase white blood cells in cancer

Analysts: Amgen most at risk from biogenerics

No drugmaker stands to lose more to biotech copycat drugs than Amgen. Analysts think its blockbuster blood-cell boosters Epogen and Neupogen will be among the first drugs copied in the U.S., once